Paul Brownstone
Clinical Pharmacology · Boulder, CONPI 1780789214
Payments from drug & device makers
Across 330 payments — averaging $43,156 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8.4M
- Eli Lilly$4.6M
- AbbVie$1.2M
- Amgen$4K
- Teva Pharmaceuticals USA, Inc.$2K
- Pfizer$2K
- plus $4K from 3 others
Across 6 payments — averaging $7476.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$45K
What the payments were for
- Food & beverage$32100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $8,371,738 |
| Eli Lilly | 40 | $4,610,039 |
| AbbVie(2 entities) | 263 | $1,248,144 |
| Amgen | 4 | $3,895 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,825 |
| Pfizer | 1 | $1,785 |
| Currax Pharmaceuticals LLC | 2 | $1,600 |
| Avanir Pharmaceuticals, Inc. | 1 | $1,463 |
| Biogen | 1 | $1,065 |
How this compares
Too few clinical pharmacology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.